Ocular Therapeutix (OCUL) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$65.2 million.

  • Ocular Therapeutix's Income from Continuing Operations fell 3313.13% to -$65.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$263.5 million, marking a year-over-year decrease of 5962.16%. This contributed to the annual value of -$263.5 million for FY2025, which is 5962.16% down from last year.
  • Latest data reveals that Ocular Therapeutix reported Income from Continuing Operations of -$65.2 million as of Q4 2025, which was down 3313.13% from -$68.0 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Income from Continuing Operations registered a high of -$19.5 million during Q1 2022, and its lowest value of -$68.0 million during Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's median Income from Continuing Operations value was -$22.9 million (recorded in 2022), while the average stood at -$34.4 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first soared by 1094.77% in 2022, then crashed by 11550.88% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Income from Continuing Operations stood at -$19.7 million in 2021, then fell by 5.38% to -$20.8 million in 2022, then dropped by 9.42% to -$22.7 million in 2023, then crashed by 115.51% to -$49.0 million in 2024, then plummeted by 33.13% to -$65.2 million in 2025.
  • Its Income from Continuing Operations stands at -$65.2 million for Q4 2025, versus -$68.0 million for Q3 2025 and -$67.2 million for Q2 2025.